What question did this study set out to answer?

This review aims to evaluate the prevalence and risk factors for invasive fungal infections in patients treated with BTKIs.

April 11, 2026Blood AdvancesOpen Access

Invasive Fungal Infections Following Bruton Tyrosine Kinase Inhibitor Treatment: A Systematic Review and Meta-analysis

View Full Paper

Ask AI

Bookmark

This review aims to evaluate the prevalence and risk factors for invasive fungal infections in patients treated with BTKIs.
Conducted a systematic review and meta-analysis of 88 studies
Included data from 23,737 patients
Calculated pooled prevalence of proven/probable IFIs
Examined risk factors associated with IFIs
Pooled prevalence of proven/probable IFIs was 2.83%
Highest prevalence in patients with central nervous system lymphoma (9.02%)
Concurrent corticosteroid use significantly associated with IFIs (OR 5.03)
Prevalence of fungal infections varied among BTKI agents, from 0.62% to 2.50%

No takes yet. Share an insight, caveat, or question.

Systematic review analyzes invasive fungal infections in patients on BTKIs, highlighting risks and implications.

Srisurapanont et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark